Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions

Cancer immunotherapy has been revolutionized by the development of monoclonal antibodies (mAbs) that inhibit interactions between immune checkpoint molecules, such as programmed cell-death 1 (PD-1), and its ligand PD-L1. However, mAb-based drugs have some drawbacks, including poor tumor penetration...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun-Hye, Kawamoto, Masuki, Dharmatti, Roopa, Kobatake, Eiry, Ito, Yoshihiro, Miyatake, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279355/
https://www.ncbi.nlm.nih.gov/pubmed/32455628
http://dx.doi.org/10.3390/ijms21103639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279355/
https://www.ncbi.nlm.nih.gov/pubmed/32455628
http://dx.doi.org/10.3390/ijms21103639

Ejemplares similares